The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range?
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 25261182.
- Also identified by DOI 10.1016/j.arth.2014.08.032 and PMC identifier 4324127.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purpose of this study was to determine the percentage of time that patients are therapeutic when prescribed warfarin for chemical thromboprophylaxis following a hip or knee arthroplasty procedure. One hundred eighty-four patients receiving warfarin for 4weeks postoperatively, dosed using a Web-application accounting for patient demographics, INR levels, and concomitant medication use, were included. Patients with a target INR range between 1.7 and 2.7 were therapeutic for only 54.4% of the time (32.5% subtherapeutic, 13.0% supratherapeutic) while patients with a target INR range between 2.0 and 3.0 were therapeutic for only 45.9% of the time (39.2% subtherapeutic, 14.8% supratherapeutic). Patients receiving warfarin for chemical thromboprophylaxis are within their targeted INR range for only a limited period of time during their postoperative course.
Medical subject headings
- Anticoagulants
- Arthroplasty, Replacement, Hip
- Arthroplasty, Replacement, Knee
- International Normalized Ratio
- Venous Thrombosis
- Warfarin
Anatomy
- hip
- knee